164 related articles for article (PubMed ID: 24917554)
21. Complete response of a recurrent-metastatic liposarcoma with dedifferentiated histological features following the administration of trabectedin and review of literature.
Kus T; Aktas G; Kalender ME; Tutar E; Ulker E; Camci C
J Cancer Res Ther; 2015; 11(4):974-6. PubMed ID: 26881560
[TBL] [Abstract][Full Text] [Related]
22. Mechanisms of responsiveness to and resistance against trabectedin in murine models of human myxoid liposarcoma.
Mannarino L; Craparotta I; Ballabio S; Frapolli R; Meroni M; Bello E; Panini N; Callari M; Sanfilippo R; Casali PG; Barisella M; Fabbroni C; Marchini S; D'Incalci M
Genomics; 2021 Sep; 113(5):3439-3448. PubMed ID: 34339817
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness and Safety of Trabectedin and Radiotherapy for Patients With Myxoid Liposarcoma: A Nonrandomized Clinical Trial.
Sanfilippo R; Hindi N; Cruz Jurado J; Blay JY; Lopez-Pousa A; Italiano A; Alvarez R; Gutierrez A; Rincón-Perez I; Sangalli C; Pérez Aguiar JL; Romero J; Morosi C; Sunyach MP; Fabbroni C; Romagosa C; Ranchere-Vince D; Dei Tos AP; Casali PG; Martin-Broto J; Gronchi A
JAMA Oncol; 2023 May; 9(5):656-663. PubMed ID: 36995731
[TBL] [Abstract][Full Text] [Related]
24. Trabectedin therapy for sarcomas.
Casali PG; Sanfilippo R; D'Incalci M
Curr Opin Oncol; 2010 Jul; 22(4):342-6. PubMed ID: 20489618
[TBL] [Abstract][Full Text] [Related]
25. Structural and functional uncoupling of the enzymatic and angiogenic inhibitory activities of tissue inhibitor of metalloproteinase-2 (TIMP-2): loop 6 is a novel angiogenesis inhibitor.
Fernández CA; Butterfield C; Jackson G; Moses MA
J Biol Chem; 2003 Oct; 278(42):40989-95. PubMed ID: 12900406
[TBL] [Abstract][Full Text] [Related]
26. Unique features of trabectedin mechanism of action.
Larsen AK; Galmarini CM; D'Incalci M
Cancer Chemother Pharmacol; 2016 Apr; 77(4):663-71. PubMed ID: 26666647
[TBL] [Abstract][Full Text] [Related]
27. Trabectedin--a targeted chemotherapy?
von Mehren M
Lancet Oncol; 2007 Jul; 8(7):565-7. PubMed ID: 17613417
[No Abstract] [Full Text] [Related]
28. Trabectedin is a promising antitumour agent for synovial sarcoma.
Yasui H; Imura Y; Outani H; Hamada K; Nakai T; Yamada S; Takenaka S; Sasagawa S; Araki N; Itoh K; Myoui A; Yoshikawa H; Naka N
J Chemother; 2016 Oct; 28(5):417-24. PubMed ID: 27077926
[TBL] [Abstract][Full Text] [Related]
29. Hsp90 inhibition by AUY922 as an effective treatment strategy against myxoid liposarcoma.
Steinmann S; Gali-Muhtasib H; Huebner K; Al-Halabi R; Abou Merhi R; Aman P; Agaimy A; Haller F; Schneider-Stock R
Cancer Lett; 2015 Oct; 367(2):147-56. PubMed ID: 26225840
[TBL] [Abstract][Full Text] [Related]
30. Biology of ovarian cancer and trabectedin mechanism of action.
Ray-Coquard I
Future Oncol; 2013 Dec; 9(12 Suppl):11-7. PubMed ID: 24195525
[TBL] [Abstract][Full Text] [Related]
31. Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin.
Colmegna B; Uboldi S; Frapolli R; Licandro SA; Panini N; Galmarini CM; Badri N; Spanswick VJ; Bingham JP; Kiakos K; Erba E; Hartley JA; D'Incalci M
Br J Cancer; 2015 Dec; 113(12):1687-93. PubMed ID: 26633559
[TBL] [Abstract][Full Text] [Related]
32. Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis® (PM00104).
Romano M; Frapolli R; Zangarini M; Bello E; Porcu L; Galmarini CM; García-Fernández LF; Cuevas C; Allavena P; Erba E; D'Incalci M
Int J Cancer; 2013 Nov; 133(9):2024-33. PubMed ID: 23588839
[TBL] [Abstract][Full Text] [Related]
33. Antimetastatic and antiangiogenic activity of trabectedin in cutaneous melanoma.
Carminati L; Pinessi D; Borsotti P; Minoli L; Giavazzi R; D'Incalci M; Belotti D; Taraboletti G
Carcinogenesis; 2019 Apr; 40(2):303-312. PubMed ID: 30544170
[TBL] [Abstract][Full Text] [Related]
34. Trabectedin in soft tissue sarcomas.
Brodowicz T
Future Oncol; 2014 Jun; 10(8 Suppl):s1-5. PubMed ID: 25048043
[TBL] [Abstract][Full Text] [Related]
35. Thrombospondin-1 (TSP-1) up-regulates tissue inhibitor of metalloproteinase-1 (TIMP-1) production in human tumor cells: exploring the functional significance in tumor cell invasion.
John AS; Hu X; Rothman VL; Tuszynski GP
Exp Mol Pathol; 2009 Dec; 87(3):184-8. PubMed ID: 19747478
[TBL] [Abstract][Full Text] [Related]
36. Diagnosis and Treatment of Myxoid Liposarcomas: Histology Matters.
Abaricia S; Hirbe AC
Curr Treat Options Oncol; 2018 Oct; 19(12):64. PubMed ID: 30362022
[TBL] [Abstract][Full Text] [Related]
37. FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro.
Künstlinger H; Fassunke J; Schildhaus HU; Brors B; Heydt C; Ihle MA; Mechtersheimer G; Wardelmann E; Büttner R; Merkelbach-Bruse S
Oncotarget; 2015 Aug; 6(24):20215-30. PubMed ID: 26036639
[TBL] [Abstract][Full Text] [Related]
38. Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53.
Moneo V; Serelde BG; Fominaya J; Leal JF; Blanco-Aparicio C; Romero L; Sánchez-Beato M; Cigudosa JC; Tercero JC; Piris MA; Jimeno J; Carnero A
J Cell Biochem; 2007 Feb; 100(2):339-48. PubMed ID: 16888811
[TBL] [Abstract][Full Text] [Related]
39. Down-regulation of vascular endothelial growth factor by tissue inhibitor of metalloproteinase-2: effect on in vivo mammary tumor growth and angiogenesis.
Hajitou A; Sounni NE; Devy L; Grignet-Debrus C; Lewalle JM; Li H; Deroanne CF; Lu H; Colige A; Nusgens BV; Frankenne F; Maron A; Yeh P; Perricaudet M; Chang Y; Soria C; Calberg-Bacq CM; Foidart JM; Noël A
Cancer Res; 2001 Apr; 61(8):3450-7. PubMed ID: 11309307
[TBL] [Abstract][Full Text] [Related]
40. The activity of trabectedin as a single agent or in combination with everolimus for clear cell carcinoma of the ovary.
Mabuchi S; Hisamatsu T; Kawase C; Hayashi M; Sawada K; Mimura K; Takahashi K; Takahashi T; Kurachi H; Kimura T
Clin Cancer Res; 2011 Jul; 17(13):4462-73. PubMed ID: 21622721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
